Nascent Biotech, Inc.
NBIO
$0.0007
-$0.0001-12.50%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 5.70% | 25.47% | 22.17% | -117.16% | -54.62% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -90.37% | -71.87% | -23.84% | 198.13% | 596.18% |
| Total Other Non-Cash Items | 146.80% | 3,050.00% | -127.54% | -113.25% | -248.80% |
| Change in Net Operating Assets | -8,887.50% | 151.61% | -46.89% | -325.76% | 97.86% |
| Cash from Operations | 16.07% | 33.64% | -10.20% | -158.61% | -284.05% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -86.66% | -88.35% | -88.35% | -100.00% | 279.10% |
| Total Debt Repaid | -45.45% | -45.45% | 15.79% | 78.97% | 8.33% |
| Issuance of Common Stock | 2,501.67% | 650.48% | 602.40% | 590.38% | -59.46% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -200.00% |
| Cash from Financing | -5.71% | -25.68% | -22.76% | -19.76% | 398.31% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 127.92% | 157.07% | -88.31% | -116.48% | -10.47% |